No News is Good News — Peregrine Pharma

Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) fell about 80% yesterday after the company revealed that there were discrepancies in the data reported on the company's Phase II trial of its lung-cancer drug bavituximab. That was after the company reported promising results earlier this month.

Today the stock rose as much as 50% as some investors clearly smell a bargain. Peregrine had a similar problem with the data from this trial earlier this year and now faces at least one and probably more lawsuits based on yesterday's announcement of the bad data.

Another drug maker, Astex Pharmaceuticals Inc. (NASDAQ: ASTX) cancelled trials on its own small-cell lung cancer drug after the company's Phase II trials failed to meet expectations. Bristol-Meyers Squibb (NYSE: BMY) is working on a different type of drug that has been shown to reduce tumor mass in 18% of lung cancer patients in Phase I trials.

Shares of Peregrine are up 44% at around noon today at $1.67 in a 52-week range of $0.39 to $5.50. Shares closed at $1.16 last night.

Paul Ausick


Filed under: 24/7 Wall St. Wire, Drug companies, Pharmaceuticals Tagged: ASTX, BMY, PPHM
Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.